




































































































































































































































Age	in	y,	mean	(SD)	 64.4	(13.5)	 69.9	(10.0)	 <0.001	
Women,	n	(%)	 14,285	(50.8)	 1,223	(62.5)	 <0.001	
Caucasian,	n	(%)	†	 18,095	(91.8)	 1,406	(91.8)	 0.92	
Body	mass	index	in	kg/m2,	mean	(SD)	‡	 26.6	(4.2)	 26.8	(4.3)	 0.072	
Thyroid	stimulating	hormone	in	mIU/L,	mean	(SD)	 1.81	(0.91)	 6.68	(2.59)	 <0.001	
Present	or	former	smoker,	n	(%)	 15,799	(56.2)	 980	(50.1)	 <0.001	
Systolic	blood	pressure	in	mmHg,	mean	(SD)	§	 139.2	(21.5)	 139.6	(22.4)	 0.36	
Total	cholesterol	in	mmol/l,	mean	(SD)	||		 6.08	(1.67)	 5.94	(1.38)	 <0.001	
Cardiovascular	disease,	n	(%)	 4,928	(17.5)	 443	(22.6)	 <0.001	
Heart	failure,	n	(%)	 655	(2.3)	 59	(3.0)	 0.054	
Stroke,	n	(%)	 624	(2.2)	 61	(3.1)	 0.010	
Diabetes,	n	(%)	 2,108	(7.5)	 196	(10.0)	 <0.001	
Antihypertensive	medication,	n	(%)	 10,593	(37.7)	 878	(44.8)	 <0.001	
Lipid-lowering	medication,	n	(%)	 3,772	(13.4)	 305	(15.6)	 0.007	














































































































































































































































































































































































































P	for	Trend	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	 	































P	for	Interaction	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	 	































P	for	Interaction	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	 	































P	for	Interaction	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	 	
Thyroxine	use	at	
BL	































































































































Age	 	 	 	 	 	 	 	 	 	 	






















P	for	Trend	 	 	 0.97	 0.97	 	 0.97	 0.97	 	 0.97	 0.97	
Sex	 	 	 	 	 	 	 	 	 	 	






















P	for	Interaction	 	 	 0.64	 0.81	 	 0.64	 0.81	 	 0.64	 0.81	
Race	†	 	 	 	 	 	 	 	 	 	 	

















(0.05-3.07)	 0/10	 NA	 NA	
P	for	Interaction	 	 	 0.037	 0.033	 	 0.037	 0.033	 	 0.037	 0.033	
Previous	CVD	 	 	 	 	 	 	 	 	 	 	






















P	for	Interaction	 	 	 0.78	 0.74	 	 0.78	 0.74	 	 0.78	 0.74	
Thyroxine	use	at	BL	 	 	 	 	 	 	 	 	 	 	
















































































































































Age,	y	 	 	 	 	 	 	 	 	 	 	 	 	






















P	for	Trend	 	 	 	 	 0.16	 0.15	 	 0.16	 0.15	 	 0.16	 0.15	
Sex	 	 	 	 	 	 	 	 	 	 	 	 	






















P	for	Interaction	 	 	 	 	 0.16	 0.18	 	 0.16	 0.18	 	 0.16	 0.18	
Race	†	 	 	 	 	 	 	 	 	 	 	 	 	






















P	for	Interaction	 	 	 	 	 0.93	 0.98	 	 0.93	 0.98	 	 0.93	 0.98	
Previous	CVD		 	 	 	 	 	 	 	 	 	 	 	 	






















P	for	Interaction	 	 	 	 	 0.068	 0.084	 	 0.068	 0.084	 	 0.068	 0.084	
Thyroxine	use	at	
BL	 	 	 	 	 	 	 	 	 	 	 	 	






















P	for	Interaction	 	 	 	 	 0.53	 0.58	 	 0.53	 0.58	 	 0.53	 0.58	
Abbreviations:	Adj,	adjusted;	AF,	atrial	fibrillation;	BL,	baseline;	CI,	confidence	interval;	CVD,	cardiovascular	disease;	E,	events;	HR,	hazard	ratio;	NA,	data	not	applicable;	P,	
participants;	ref.,	reference;	TSH,	thyroid-stimulating	hormone	
*	This	analysis	was	restricted	to	normal	thyroid	function,	i.e.	TSH	and	thyroxine	in	the	reference	range.	From	the	overall	sample	a	total	of	9164	participants	were	excluded	for	
this	analysis	with	either	missing	measurements	of	fT4	or	thyroid	function	outside	the	reference	range.	479	participants	of	the	Cardiovascular	Health	Study,	59	of	the	
Osteoporotic	Fractures	in	Men	Study,	32	of	the	Bari	Study,	137	of	the	Leiden	85+	Study,	125	of	the	Study	of	Health	in	Pomerania,	42	of	the	InChianti	Study,	365	of	the	
Rotterdam	Study,	897	of	the	EPIC-Norfolk	Study,	and	57	of	the	Busselton	Health	Study.	In	participants	of	the	Health	ABC	Study,	fT4	was	measured	only	in	TSH	³	7.0	mIU/L;	
therefore	all	2346	participants	were	excluded	for	this	analysis.	In	the	PROSPER	Study,	fT4	was	measured	only	in	participants	with	TSH	<0.45mIU/l	or	TSH	³4.5mIU/l;	therefore,	
4625	participants	were	excluded	from	this	analysis.	
†	African	Americans,	Hispanics,	Asian,	and	others	were	considered	as	non-white	population.	Data	on	race	were	missing	for	all	participants	of	the	SHIP	study,	the	InChianti	
Study,	and	the	PROSPER	Study,	51	participants	of	the	Rotterdam	Study	and	37	of	the	EPIC-Norfolk	Study.	
‡	Previous	cardiovascular	was	defined	as	a	history	of	stroke,	transient	ischemic	attack,	myocardial	infarction,	angina	pectoris,	coronary	angioplasty,	bypass	surgery.	Participants	
without	any	of	these	events	were	considered	having	no	previous	cardiovascular	disease.	
§	Adjusted	for	age,	sex,	systolic	blood	pressure,	current	and	former	smoking,	diabetes,	total	cholesterol	and	prevalent	cardiovascular	disease.	
||	542	participants	with	available	measurement	of	fT4	and	normal	thyroid	function	were	on	thyroxine	at	baseline:	167	participants	of	the	CHS,	33	of	the	MrO2,	6	of	the	Bari,	5	
of	the	Leiden	85+	Study,	76	of	SHIP,	11	of	the	InChianti	Study,	9	of	the	Rotterdam	Study,	8	of	the	PROSPER	Study,	224	of	the	EPIC-Norfolk	Study,	and	3	of	the	Busselton	Health	
Study.	
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Participants	with	euthyroidism	or	
subclinical	hypothyroidism	and	available	
data	on	AF	outcomes	and	no	AF	at	
baseline		
(n	=	31,262)	
Exclude	participants	with	overt	thyroid	
dysfunction:	
Overt	hypothyroidism	(n	=	438)	
Overt	hyperthyroidism	(n	=	368)	
Exclude	participants	with	subclinical	
hyperthyroidism	(n	=	2,023)	
Participants	with	euthyroidism	or	
subclinical	thyroid	dysfunction	
(n	=	36,278)	
Participants	with	available	TSH	
measurements									
(n	=	37,151)	
	
Exclude	participants	with:	
Both	TSH	and	fT4	below	normal	range	(n	=	47)	
Both	TSH	and	fT4	above	normal	range	(n	=	20)	
Exclude	participants	with	prevalent	AF	at	
baseline	(n	=	1,397)	
Exclude	participants	with	missing	data	on	
incident	AF	outcomes	(n	=	1,596)	
Final	study	population	for	the	main	
analysis	
participants	with	euthyroidism	or	
subclinical	hypothyroidism,	without	
thyroid	medication	at	baseline,	without	
AF	at	baseline,	with	available	data	on	AF	
outcomes	
(n	=	30,085)	
Exclude	participants	with	thyroxine	or	anti-
thyroid	medication	at	baseline	(n	=	1,177)	
Participants	with	euthyroidism	or	
subclinical	hypothyroidism	
(n	=	34,255)	
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Records	identified	through	
database	searching*	
(n	=	1418)	
Additional	record	identified	
through	other	sources	†	
(n=8)		
Records	screened	(n	=	1400)		
Studies	for	which	IPD	were	sought								
(n	=	13)	
Records	excluded	based	on	title	and	abstract	(no	
prospective	study	on	the	association	between	
thyroid	hormones	and	atrial	fibrillation)														
(n	=	1352)	
IPD	
Studies	included	(n	=	11)	
Participants	included	(n	=	30,085)	
Participants	excluded	(n	=	20,987)	
because	of	not	meeting	inclusion	
criteria	
Full-text	articles	excluded	(n	=	34)	due	to:	‡	
Review,	meeting	abstract,	poster	or	
editorial	(n	=	10)		
No	prospective	cohort	study	(n	=	8)	
No	measurement	of	both	serum	TSH	and	
thyroxine	at	baseline	(n	=	2)	
No	explicit	assessment	of	atrial	fibrillation	
outcome	events	(n	=	9)	
Studies	assessing	only	postoperative	atrial	
fibrillation	events	(n	=	5)	
Full-text	articles	assessed	for	eligibility	
(n	=	48)	
Records	after	duplicates	removed									
(n	=	1400)	
Studies	for	which	IPD	were	not	or	not	fully	
provided	(n	=	2)	||	
Number	of	participants	(n	=	10,499)	||	
 
Studies	for	which	IPD	were	provided				
(n	=	11)	
Participants	from	whom	data	were	
provided	(n	=	51,072)	
Participants	for	whom	no	data	were	
provided	(n	=	0)	
Studies	for	which	aggregate	data	were	available	
(n	=	2)	||	
Number	of	participants	(n	=	10,499)	||	
 
Aggregate	data	
Studies	included	in	analysis	(n	=	2)		
Participants	included	(n	=	10,499)	#	
Studies	excluded	due	to	inclusion	of	the	same	
population	(n	=	1)	§	
Studies	meeting	inclusion	criteria											
(n	=	14)	
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Figure	Legends	
Supplemental	Figure	1.	Selection	of	the	final	study	population	for	the	individual	participant	data	analysis.		
Abbreviations:	AF,	atrial	fibrillation;	fT4,	free	thyroxine;	TSH,	thyroid	stimulating	hormone.	
Supplemental	Figure	2.	Study	flow	diagram.	Studies	evaluated	for	inclusion	in	the	IPD	analysis,	adapted	from	
PRISMA-IPD	Statement	Flow	Diagram.3		Abbreviations:	IPD,	individual	participant	data	
*	Until	July	27,	2016	
†	from	prospective	cohorts	participating	in	the	international	Thyroid	Studies	Collaboration	that	had	prospective	
data	on	atrial	fibrillation	outcomes	
‡	List	of	excluded	full	text	articles	in	Supplemental	Table	2	
§Two	articles	retrieved	through	database	searching	included	the	same	population	of	the	Cardiovascular	Health	
Study	4,5	
||	Data	on	1759	euthyroid	and	subclinically	hypothyroid	participants	from	the	Framingham	Heart	Study	6	were	
not	provided	free	of	charge.		Among	the	8740	participants	included	in	the	Rotterdam	Study,7	data	of	the	1426	
participants	included	in	the	Rotterdam	Study	Cohort	I	that	had	been	previously	published	8	were	provided,	
whereas	data	on	7314	participants	of	the	Rotterdam	Study	Cohorts	II	and	III	were	not	provided.	
#	Chaker	and	colleagues	reported	aggregate	data	of	the	Rotterdam	Study	Cohorts	I,	II,	and	III,	therefore	the	
individual	participant	data	of	Rotterdam	Cohort	I	(that	were	included	in	our	main	analysis)	were	excluded	for	
the	sensitivity	analysis	including	the	aggregate	data.7	
Supplemental	Figure	3.	Restricted	cubic	spline	plot	for	the	association	between	continuous	concentrations	of	
thyroid	stimulating	hormone	and	atrial	fibrillation.	The	p-value	for	a	non-linear	trend	was	0.067.	Abbreviations:	
TSH,	thyroid	stimulating	hormone.		
Supplemental	Figure	4.	Restricted	cubic	spline	plot	for	the	association	between	continuous	concentrations	of	
free	thyroxine	within	the	reference	range	and	atrial	fibrillation.	The	p-value	for	a	non-linear	trend	was	£0.001.	
Abbreviations:	fT4,	free	thyroxine;	SD,	standard	deviation.		
Supplemental	Figure	5.	Funnel	plot	for	the	association	between	free	thyroxine	within	the	reference	range	and	
atrial	fibrillation.	Estimates	of	the	highest	fT4	quartile	compared	to	the	lowest	fT4	quartile	were	considered.	
Abbreviations:	fT4,	free	thyroxine;	SE,	standard	error.	
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